Hengrui Pharma Signs Exclusive License With Novo For Once-Weekly Oral GLP-1/GIP Agonist HRS-1596, Featuring $300M Upfront In Up To $2.6B Deal

Hengrui Pharma has signed an exclusive licensing agreement with Novo for HRS-1596, a phase I-ready GLP-1/GIP dual receptor agonist intended for once-weekly oral dosing. The deal includes an upfront payment of $300 million and has a total potential value of up to $2.6 billion, which may also include potential sales royalties.